Cantor Fitzgerald initiates CytomX Therapeutics stock coverage with Overweight rating
PositiveFinancial Markets

Cantor Fitzgerald has started coverage of CytomX Therapeutics with an Overweight rating, signaling strong confidence in the company's potential for growth. This is significant as it may attract more investors and boost the stock's performance, reflecting optimism about CytomX's innovative therapies and market position.
— Curated by the World Pulse Now AI Editorial System